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Abstract
We recently found that normal human brain and low-grade astrocytomas express the receptor protein tyrosine
phosphatase mu (PTPμ) and that the more invasive astrocytomas, glioblastoma multiforme (GBM), downregulate full-
length PTPμ expression. Loss of PTPμ expression in GBMs is due to proteolytic cleavage that generates an intracellular
and potentially a cleaved and released extracellular fragment of PTPμ. Here, we identify that a cleaved extracellular frag-
ment containing the domains required for PTPμ-mediated adhesion remains associated with GBM tumor tissue. We hypo-
thesized that detection of this fragment would make an excellent diagnostic tool for the localization of tumor tissue within
the brain. To this end, we generated a series of fluorescently tagged peptide probes that bind the PTPμ fragment. The
peptide probes specifically recognize GBM cells in tissue sections of surgically resected human tumors. To test whether
the peptide probes are able to detect GBM tumors in vivo, the PTPμ peptide probes were tested in both mouse flank
and intracranial xenograft human glioblastoma tumor model systems. The glial tumors were molecularly labeled with
the PTPμ peptide probes within minutes of tail vein injection using the Maestro FLEX In Vivo Imaging System. The label
was stable for at least 3 hours. Together, these results indicate that peptide recognition of the PTPμ extracellular fragment
provides a novel molecular diagnostic tool for detection of human glioblastomas. Such a tool has clear translational appli-
cations and may lead to improved surgical resections and prognosis for patients with this devastating disease.
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Introduction
The prognosis for high-grade brain tumors such as glioblastoma multi-
forme (GBM) is extremely poor, with a median survival of approxi-
mately 1 year from diagnosis [1,2]. Several biologic characteristics
contribute to the lethality of GBM tumors, including their uncontrolled
proliferation in the restricted cranial space and their highly dispersive
nature [1,3]. Surgical resection remains the primary treatment of glial
tumors [4], and a more complete resection has been linked to improved
survival [5]. However, by the time of diagnosis, GBM cells have usually
dispersed extensively into the surrounding brain, making it difficult
for the surgeon to precisely localize the tumor margin [6]. Magnetic
resonance imaging (MRI)–guided stereotactic techniques are typically
used to maximize resection. However, MRI is limited in its ability to
detect sparse tumor cells invading surrounding normal brain [7]. Be-
cause nearly all glioblastomas recur locally, better detection and surgical
resection would likely improve patient survival. The development of
in vivomolecular imaging reagents could significantly improve glioblas-
toma detection in patients in a noninvasive fashion and facilitate more
complete resection while minimizing surgical complications.
Receptor protein tyrosine phosphatases (RPTPs) are important regu-
lators of adhesion-dependent signals [8–10]. Protein tyrosine phospha-
tase μ (PTPμ) protein is highly expressed in normal brain and plays a
role in the stabilization of cell-cell contacts [11,12]. The extracellular
segment of PTPμ contains motifs found in cell adhesion molecules,
including a meprin, A5 (neuropilin), μ domain (MAM), an immuno-
globulin (Ig) domain, and four fibronectin type III (FNIII) repeats [8].
PTPμ has a juxtamembrane domain and two tandem tyrosine phospha-
tase domains in its intracellular segment [8]. PTPμ likely transduces sig-
nals in response to adhesion that may regulate contact inhibition of
movement. PTPμ binds homophilically (i.e., the “ligand” for PTPμ
is an identical PTPμmolecule on an adjacent cell) [13–15].Cells express-
ing two very similar RPTPs, PTPκ and PTPμ, which share more than
60% amino acid sequence similarity, do not bind to one another in ag-
gregation assays [15].
The Ig domain of PTPμ is responsible for promoting homophilic
interactions [16] and proper cell surface localization [17]. The sorting
of closely related molecules such as PTPμ and PTPκ is attributed to the
MAM domain [15]. However, MAM, Ig, and the first two FNIII re-
peats are the minimal extracellular domains required for efficient cell-
cell adhesion [15,16,18–20]. Crystallographic studies demonstrated
that the MAM and Ig domains are tightly associated into what seems
to be one functional entity [19]. Additional crystal structure analysis
predicted that the adhesive interface between two PTPμ molecules is
between the MAM and Ig domains of one PTPμ molecule with the
first and second FNIII domains of the second PTPμ molecule [20].
Because of what was termed the extensive interaction interface observed
in crystal packing [20], when PTPμ is involved in cell-cell adhesion, its
binding sites are likely fully engaged.
We recently found that normal brain and primary rat astrocytes ex-
press PTPμ, but the most dispersive glial tumors, GBMs, downregulate
full-length PTPμ expression [12]. The down-regulation of PTPμ occurs
through proteolytic cleavage in human GBM tumors [21], which re-
leases the cytoplasmic domain of PTPμ from the plasma membrane.
We found that signaling through the released cytoplasmic domain was
necessary for increased migration of GBM cancer cells in vitro. PTPμ
cleavage may be an important event that deregulates normal contact
inhibition of movement. In this article, we identify the presence of an
extracellular fragment of PTPμ in human GBM tumors but not in
normal brain tissue. This extracellular fragment contains the domains
required for PTPμ-mediated homophilic cell-cell adhesion.We hypoth-
esize that detection of this fragment may facilitate the identification of
the tumor margin because it is present at the tumor edge. Therefore, we
devised a strategy to detect this extracellular PTPμ fragment by exploit-
ing what we know about PTPμ-mediated homophilic binding to gen-
erate a series of fluorescently tagged peptide probes to surface-exposed
sites of PTPμ. The peptide probes specifically recognize primary human
GBM cells in tissue sections of surgically resected tumor. The peptides
recognize GBM tumors in vivo in two different humanGBMxenografts
in nude mice. Most importantly, the peptides cross the compromised
blood-brain barrier to label intracranial GBM tumors. These results in-
dicate that the cleaved PTPμ extracellular fragment is a novel biomarker
ofGBMcells that can be used as amolecular diagnostic imaging agent to
noninvasively detect the tumor margin of human glioblastomas in vivo.
Materials and Methods
Peptide Synthesis and Conjugation
SBK1, SBK2, SBK3, and SBK4 peptides either were synthesized on
a synthesizer (Model 433A; Applied Biosystems, Foster City, CA) by
Dr. Marty Pagel and his laboratory in the Department of Biomedical
Engineering, Case Western Reserve University or were purchased from
Genscript Corporation (Piscataway, NJ). An N-terminal glycine residue
was added to peptides SBK1, SBK2 and SBK3 during synthesis. After
synthesis, the N-terminal glycine residue of each peptide was specifi-
cally coupled to Texas Red (TR)-X (single isomer) or Alexa-750 succi-
nimidyl ester dye (Molecular Probes, Inc, Eugene, OR), which has a
five-carbon spacer between the succinimide group that couples to the
N-terminal amine and the fluorophore.
Human Brain Tissue Protein Extraction
Using a Food and Drug Administration–approved computer naviga-
tional device and software (BrainLab Vector Vision 2 and i-Plan 2.0,
Westchester, IL), the neurosurgeon coregistered multiple scalp points
with volumetric RAGE T1 ± gadolinium MRI (1.5-mm segments/
0 skips) obtained the day before surgery using a standard technique
(Z-Touch, BrainLab, Inc., Westchester, IL). After achieving precision
of 1 mm or less and confirmation using various objective skull land-
marks, surgery was performed using stereotactic techniques. After path-
ologic confirmation of GBM was obtained, the stereotactic device was
used to identify the edge and center of the gadolinium-enhanced tumor
mass, and paired specimens of approximately 100mg eachwere preserved
in liquid nitrogen or formalin-paraffin, respectively. In some cases, none-
loquent brain was also identified and similarly preserved if it was part
of the region to be resected. Similarly, discarded tissue from patients
undergoing cortical resections for intractable epilepsy was collected for
noncancerous “normal” tissue after the neuropathologists released the
sample. Only discarded tissue was used, and approval was obtained
from the University Hospitals CaseMedical Center and Case Compre-
hensive Cancer Center’s Institutional Review Board. After tissue resec-
tion, the samples were snap frozen and thawed on ice in lysis buffer,
and protein was extracted as previously described [12]. Mouse flank
Gli36Δ5 or LN-229 tumors were excised, snap frozen, and then lysed
as described [12] using a PRO 200 tissue tearor (PRO Scientific, Inc,
Monroe, CT). All samples were separated by SDS-PAGE and trans-
ferred to nitrocellulose for immunoblot analysis with antibodies gener-
ated with a peptide corresponding to amino acids 42 to 60 within the
MAM domain in the extracellular segment of PTPμ (BK9) [16].
306 Detection of GBM with PTPμ Probes Burden-Gulley et al. Neoplasia Vol. 12, No. 4, 2010
Peptide Labeling of Human Brain Tissue
Human glioblastoma or noncancerous “normal” epilepsy tissue
samples were immediately fixed in 10% neutral-buffered formalin
(Sigma-Aldrich, St. Louis, MO). Tissues were ethanol-dehydrated and
paraffin-embedded. Tissue sections were cut at 5-μm intervals and
stored at room temperature (RT). Before staining, tissue sections were
deparaffinized and blocked with 2% goat serum in PBS for 20 minutes
at RT. PTPμ-TR peptides were diluted in block buffer and incubated
with the tissue sections for 1 hour at RT in the dark. The sections were
rinsed with PBS, coverslipped with Citifluor Antifadent Mounting
Medium, AF1 (Electron Microscopy Sciences, Hatfield, PA) and imaged
immediately at 40× on a Nikon TE-200 inverted microscope (Nikon In-
struments Inc., Melville, NY), using a SPOT-RT camera and SPOTsoft-
ware version 3.2 (Diagnostic Instruments, Inc, Sterling Heights, MI).
High-magnification phase and fluorescent images were obtained using
the same exposure settings between multiple experiments. The working
concentrations for the peptides were determined empirically for tissue
staining and are as follows: SBK1-TR, 40 μM; SBK2-TR, 10 μM;
SBK3-TR, 10 μM; and SBK4-TR, 3.3 μM. The SBK4-TR peptide
was the most effective in labeling human GBM tissue sections.
Antibody-Blocking Experiments
To block PTPμ binding sites, human tumor tissue sections were pre-
incubated for 1 hour at RT with BK2 monoclonal antibody, raised
against amino acids 42 to 60 within the MAM domain of PTPμ [16],
before incubating with SBK2-TR (10 μM) or SBK4-TR (3.3 μM)
peptide in block buffer for 1 hour at RT in the dark. Tissue sections were
rinsed and imaged as described above.
Heterotopic Xenograft Flank Tumors
HumanGli36Δ5 glioblastoma cells constitutively overexpress the vIII
mutant forms of the EGFR gene [22]. Human LN-229 glioblastoma
cells were obtained from American Type Culture Collection (Manassas,
VA). Gli36Δ5 or LN-229 cells were harvested for flank implantation
by trypsinization. In some experiments, the cells were infected with
lentivirus to express green fluorescent protein (GFP) [23] 48 hours be-
fore harvesting. The cells (2 × 106 cells for flank tumor implants) were
resuspended in a 1:1 dilution of PBS and Matrigel (BD Biosciences,
Franklin Lakes, NJ) for a total volume of 250 to 300 μl per flank tumor
implant per animal.
NIH athymic nude female mice (5-8 weeks and 20-25 g on arrival;
NCI-NIH) were maintained at the Athymic Animal Core Facility at
Case Western Reserve University according to institutional policies.
All animal protocols were approved by the Institutional Animal Care
and Use Committee (IACUC). For flank tumor implants, mice were
anesthetized with inhaled isofluorane-oxygen for immobilization. The
Matrigel-cell mixture was loaded into a 1-ml syringe fitted with a 26-
gauge needle and kept on ice. The mixture was injected subcutaneously
in the right flank region of the mouse.
Peptide Labeling of Mouse Flank Tumor Sections
NIH athymic nude female mice implanted with Gli36Δ5 or LN-229
flank tumors for 2 to 3 weeks were anesthetized with inhaled isoflurane-
oxygen and sacrificed by decapitation. Flank tumors were then excised,
fixed in 4% paraformaldehyde in PEM buffer (80 mM Pipes, 5 mM
EGTA, 1 mM magnesium chloride, 3% sucrose), pH 7.4, embedded
in OCT, and cryosectioned at 5-μm intervals. Slides were stored at
−20°C. For peptide labeling experiments, the slides were thawed and
incubated with peptide diluted to 100 to 200 μM as described above.
In Vivo Imaging of Flank Tumors
Nude mice with Gli36Δ5 or LN-229 flank tumors were imaged at
9 to 28 days after cell injection. Fluorophore-conjugated PTPμ pep-
tides were diluted to 100 μM (SBK2-Alexa) or 200 μM (SBK1-TR,
SBK3-TR, SBK4-TR, and scrambled SBK2-TR control peptide) in
PBS and injected (total volume, 150 μl) through a lateral tail vein using
a 28-gauge insulin syringe. In the animals containing GFP-expressing
tumor cells, Alexa-750–labeled peptide was used owing to its limited
spectral overlap with GFP. Spectral fluorescence images were obtained
using the Maestro FLEX In Vivo Imaging System using the appropriate
filters for GFP (tumor; excitation = 445-490 nm, emission = 515 nm
long-pass filter, acquisition settings = 500-720 in 10-nm steps), TR
(peptide; excitation = 575-605 nm, emission = 645 nm; acquisition set-
tings = 630-850 in 10-nm steps), or Alexa-750 (peptide; excitation =
671-705 nm, emission = 750 nm long-pass filter, acquisition settings =
730-950 in 10-nm steps). Acquisition settings were 53 milliseconds for
GFP and 1000 milliseconds for either TR or Alexa-750–labeled peptide.
Before peptide injection, background images were acquired through
the skin to provide autofluorescence spectra. After peptide injection, fluo-
rescence images were acquired at 5- to 15-minute intervals during 2 to
3 hours. The multispectral fluorescence images were background-
subtracted and unmixed, using Maestro software (Cambridge Research
& Instrumentation, Inc, Woburn, MA), to spectrally separate the auto-
fluorescence animal signal from the peptide signals. Regions of interest
(ROIs) were selected over the tumor or nontumor skin. Pixel values for
the peptide signal, in photonsmeasured at the surface of the animal, were
determined within these ROIs.Higher pixel values corresponded to pres-
ence of tumor. Pixel values in the tumor ROIs were normalized to the
nontumor ROI and peptide concentration and were then plotted. Each
PTPμ peptide was tested on a minimum of three animals containing
Gli36Δ5 and three animals containing LN-229 flank tumors. Statistical
analyses were performed usingMicrosoft Excel and an unpaired Student’s
t test.
Orthotopic Xenograft Intracranial Tumors
Gli36Δ5-GFP or LN-229-GFP cells were harvested for intracranial
implantation by trypsinization and concentrated to 1 × 105 cells per
microliter of PBS. For brain tumor implants, NIH athymic nude fe-
male mice were anesthetized by intraperitoneal injection of 50 mg/kg
ketamine/xylazine and fitted into a stereotaxic rodent frame (DavidKopf
Instruments, Tujunga, CA). A small incision was made just lateral to
midline to expose the bregma suture. A small (0.7 mm) burr hole was
drilled at AP = +1, ML = −2.5 from bregma. Glioblastoma cells were
slowly deposited at a rate of 1 μl/min in the right striatum at a depth
of −3 mm from dura with a 10-μl syringe (26-gauge needle; Hamilton
Co, Reno, NV). The needle was slowly withdrawn, and the incision
was closed with sutures.
In Vivo Labeling of Intracranial Tumors
Nude mice with Gli36Δ5-GFP or LN-229-GFP intracranial tumors
were imaged at 9 to 12 days after GBM cell implant. Fluorophore-
conjugated PTPμ peptides were injected through the tail vein as
described above. After a 25-minute incubation for clearance of un-
bound PTPμ peptide, the animals were sacrificed, and the brains were
removed and imaged either whole or sliced into coronal sections at 1-mm
intervals. Individual brain sections containing tumor were placed on
a black slide and examined using the Maestro FLEX In Vivo Imaging
System as described above. Untreated brains containing Gli36Δ5-GFP
intracranial tumors were used to provide autofluorescence spectra. ROIs
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were selected over the tumor region in each brain slice. Pixel values for
the peptide signal, in photons measured from the slice, were deter-
mined within these ROIs. The multispectral fluorescence images were
background-subtracted and analyzed using the Maestro software as de-
scribed previously. Statistical analyses were performed using Microsoft
Excel and an unpaired Student’s t test.
Results
An Extracellular Fragment of PTPμ Is Detected in
Human Glioblastomas
We recently demonstrated that full-length PTPμ is downregulated
in human GBM tumors [12] through proteolytic processing [21]. We
tested whether any extracellular fragments of PTPμ could be detected in
human GBM tumor tissue lysates using the PTPμ-specific extracellular
monoclonal antibody, BK9 [16]. BK9 was generated against the MAM
domain of PTPμ [16]; it is specific to PTPμ and fails to cross-react even
with closely related type IIb RPTPs (data not shown). Here, we show
that a 55-kDa protein is recognized by BK9 (Figure 1A). Another
PTPμ-specific polyclonal antibody, 494, also recognizes the 55-kDa
protein (data not shown). The MAM domain of PTPμ is 160 amino
acids in length, and the Ig and FNIII domains are both approximately
80 to 90 amino acids long; therefore, the 55-kDa fragment likely con-
tains the MAM, Ig, and the first two FNIII repeats (Figure 1C ). On
the basis of these observations, the 55-kDa protein is an extracellular
fragment of PTPμ.
The 55-kDa extracellular fragment of PTPμ is detected in the center
and edge of the resected GBM tumor at much higher levels than in
normal cortical brain tissue from the same patient (Figures 1A and
4A). Densitometry indicates that the center and edge of GBM tumors
contain approximately two-fold higher levels of the extracellular frag-
ment (Figure 1A). The human edge samples were determined by
pathologists to contain fewer tumor cells proportionally to normal cells,
suggesting that the PTPμ extracellular fragment is concentrated at the
tumor edge andmay be exploitable as a biomarker of the tumor margin.
Figure 1. A 55-kDa extracellular fragment of PTPμ is detected in human glioblastoma tissue. (A) GBM tumors from three patients were
divided into center (ctr) and edge samples, lysed, separated by SDS-PAGE, and immunoblotted using an antibody against theMAM domain
of PTPμ. Noncancerous normal cortex (ctx) from the same patients was loaded for comparison. Equal protein load was verified by stripping
and reprobing the immunoblot with an antibody to vinculin. Densitometry values for the 55-kDa extracellular fragment are shown under each
GBM tumor center and edge lane and are normalized to the normal cortex from the same patient. (B) LN-229 or Gli36Δ5 xenograft flank
tumor protein extracts were immunoblotted as described above. Human GBM tumor tissue (T) was loaded on the same blot for comparison.
The numbers on the left side of each immunoblot correspond to the molecular weight in kilodaltons. (C) PTPμ structure and peptide probe
sequences. PTPμ is a transmembrane protein that mediates efficient cell-cell adhesion through the MAM domain, Ig domain, and FNIII
repeats within its extracellular segments. The scissors indicate the approximate site where PTPμ is cleaved to generate a 55-kDa N-terminal
extracellular fragment. The sequence is shown for the PTPμMAM and Ig domains. The highlighted regions indicate the sequences used to
generate PTPμ peptide probes. (D) Crystal structure of the Ig and MAM domains of PTPμ (PDB ID:2V5Y). SBK1 (red) and SBK2 (green) were
derived from the N-terminal MAM domain, whereas SBK3 (magenta) and SBK4 (camel) were from the Ig domain.
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Peptide Design and Optimization
PTPμ-dependent cell adhesion requires the MAM, Ig, and first two
FNIII domains, all of which are predicted to be present in the 55-kDa
cleaved fragment [15–20]. On the basis of crystallographic data indi-
cating which residues are surface-exposed on PTPμ [19,20], and our
binding studies [16], we designed peptide probes that would bind
homophilically to the adhesive MAM and Ig domains contained within
the cleaved fragment of the extracellular segment of PTPμ (Figure 1, C
and D). Four peptides derived from the MAM (SBK1 and SBK2 pep-
tides) or Ig (SBK3 and SBK4 peptides) domains of PTPμ were gener-
ated (Figure 1,C andD). As a control, a scrambled version of the SBK2
peptide was also synthesized. The peptides were fluorescently labeled
with TR-X succinimidyl ester dye on the N-terminus.
Detection of Human Glioblastomas with the PTPμ
Peptide Probes
To examine the localization of the 55-kDa PTPμ fragment within
GBM tumors, the TR-conjugated peptides were used as probes to label
sections of GBM or noncancerous human brain obtained from epilepsy
patients. The PTPμ-TR peptides each recognized GBM tissue to vary-
ing degrees, although the best labeling occurred with peptides SBK2
and SBK4 (Figures 2 and 3). Effective peptide concentrations for tissue
labeling were determined by dilution histochemical analyses using
human GBM tissue sections and indicated that the range of 3 to 40 μM
was effective. The SBK1 peptide weakly labeled GBM tissue but did
not label the noncancerous human brain (Figure 2). The SBK2, SBK3,
and SBK4 peptides typically labeled the parenchyma above back-
ground with particularly bright labeling of the cell bodies (Figures 2
and 3). Endothelial cells express high levels of PTPμ [24–28] and were
also brightly labeled within the tumor (Figures 2 and 3). Two repre-
sentative GBM tumors are shown (tumors 1 and 2). Similar results
were observed in six different GBM samples (data not shown). In con-
trast, scrambled control peptide (scrambled SBK2) did not label the
GBM tissue (Figures 2 and 3). When PTPμ peptides were incubated
with sections of noncancerous brain tissue obtained from epilepsy pa-
tients, no specific structures were labeled in either white or gray matter
regions (Figures 2 and 3). Similar results were observed in six differ-
ent samples of noncancerous “normal brain” (data not shown).
The correct determination of the tumor edge is of great importance to
the neurosurgeon during tumor resection. In tissue sections from pa-
tients containing the edge ofGBMtumor, the PTPμ peptide SBK4 clearly
labeled the GBM tumor edge against the normal brain tissue background
(Figure 4A). The scrambled control peptide did not label the tumor edge
(data not shown). In normal brain tissue, when PTPμ is involved in cell-
cell adhesion, its binding sites may be fully engaged and therefore un-
available for recognition by the PTPμ peptides. Alternatively, in GBM
tissue, the extracellular domain of PTPμmay undergo a conformational
change after cleavage that allows recognition by the PTPμ peptides.
Figure 2. SBK2 peptide probe specifically recognizes human glioblastoma tissue but not normal brain. Sections of noncancerous normal
cortical brain tissue from epilepsy patients or GBM tumor were histochemically labeled with TR-conjugated SBK1, SBK2, or scrambled SBK2
peptides. Two examples of normal and GBM tissue are shown, which are representative of six different samples examined.
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The PTPμ Peptides Specifically Recognize PTPμ
To confirm that the PTPμ peptides were binding to an extracellular
fragment of PTPμ in GBM tissue, we performed antibody-blocking
experiments. To block peptide binding, we used the PTPμ-specific
monoclonal antibody, BK2, which was raised against theMAMdomain
of PTPμ and recognized native protein [16]. The BK2 antibody does
not cross-react with other closely related type IIb RPTPs (data not
shown). GBM tissue sections were preincubated with BK2 before in-
cubating with the SBK2 peptide, generated from the MAM domain,
or SBK4 peptide, generated from the Ig domain of PTPμ. Because of
the tightly associated structure of the MAM-Ig domain of PTPμ [19],
we predicted that BK2 would sterically block access of both peptides to
the extracellular fragment. Preincubation with BK2 caused a complete
block of SBK2 and SBK4 peptide binding (Figure 4B). The detection of
the extracellular PTPμ fragment on blots using both BK9 monoclonal
and 494 polyclonal antibodies and the blocking of the peptide binding
by the BK2monoclonal antibody in tissue sections demonstrate that the
SBK2 and SBK4 peptides recognize and bind to an extracellular frag-
ment of PTPμ in human GBM tissues.
Peptide Recognition of Glioblastoma-Associated PTPμ
Fragment as a Diagnostic Tool
Specific recognition of GBM cells in vivo through peptide binding
would provide a powerful diagnostic tool. We developed a xenograft
animal model system of GBM for in vivo labeling. Two GFP-expressing
human glioblastoma cell lines, LN-229 and Gli36Δ5, were injected
individually into the flanks of nudemice for the production of xenograft
tumors. At 2 to 3 weeks after injection, the tumors were excised and
homogenized for biochemical analysis. The extracellular fragment of
PTPμ is present in both LN-229 andGli36Δ5 cells when grown as flank
tumors (Figure 1B).
To observe localization of the PTPμ extracellular fragment in the
xenograft tumors, sections of fixed tumors were incubated with either
SBK2 or SBK4 peptides. The PTPμ peptides labeled both the Gli36Δ5
(Figure W1) and LN-229 (Figures 5 andW2) tumors, in a pattern that
closely overlaid the tumor cells as evidenced by GFP fluorescence. Small
clusters of labeled cells were clearly visible at the tumor edge (Figure 5);
thus, the peptides may be useful for detection of the tumor margin. The
recognition of the extracellular fragment by PTPμ peptides suggested
that this animal model was a viable system for further study in vivo.
Flank tumors provide a useful model for molecular imaging studies
owing to accessibility and ease of imaging using fluorescence detection
methods. Nude mice with Gli36Δ5 or LN-229 flank xenografts were
imaged through the skin with the Maestro FLEX In Vivo Imaging
System using the appropriate filters for GFP, TR, or Alexa-750. Back-
ground images of the flank region containing the tumor were acquired,
PTPμ peptides were administered through tail vein injection, and the
animals were imaged at regular intervals during the course of 2 to 3 hours.
Figure 3. SBK3 and SBK4 peptide probes specifically recognize human glioblastoma tissue but not normal brain. Sections of noncancerous
normal cortical brain tissue fromepilepsy patients orGBMtumorwerehistochemically labeledwith TR-conjugatedSBK3, SBK4, or scrambled
SBK2 peptides. Two examples of normal and GBM tissue are shown, which are representative of six different samples examined.
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Figure 5. Small cell clusters from LN-229 flank tumors label with PTPμ peptide SBK2. Flank tumors of LN-229 cells were excised, fixed, and
sectioned. The LN-229 cells express GFP. Binding of the TR-conjugated SBK2 peptide is shown in two tumor samples. SBK2 peptide labels
small clusters of cells in the tumor microenvironment.
Figure 4. PTPμ peptide SBK4 demarcates glioblastoma cells at the tumor edge. (A) Surgically resected humanGBM tumor edge sectionwas
labeled with TR-conjugated SBK4 peptide. Arrows in the phase image indicate the approximate position of the margin between GBM and
normal brain tissue. (B) PTPμmAbblocksSBK2andSBK4peptidebinding tohumanglioblastoma tissue. Preincubation of a PTPμextracellular
antibody raised against the MAM domain (BK2) specifically blocked SBK2-TR and SBK4-TR peptide binding to GBM tumor tissue sections.
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Fluorescence was observed throughout the tumor within 1 minute after
injection, but maximal tumor labeling occurred within 10 to 20minutes
after injection. Unbound circulating peptide was cleared from the ani-
mals quickly, resulting in a clear demarcation of tumor over the normal
tissue background (Figures 6A and 7A). In most cases, the tumor re-
mained labeled above background for at least 3 hours. The average signal
in the tumor was normalized to the average signal in nontumor skin and
plotted (Figures 6B and 7B). SBK2 peptide rapidly bound to the
Gli36Δ5-GFP tumor and remained bound at a level greater than that
in the surrounding skin during the course of the 3-hour experiment (Fig-
ure 6). Peak levels of Gli36Δ5-GFP tumor labeling were achieved in 10
to 20 minutes. Of note, similar results were obtained when the tumor
was composed of LN-229-GFP human GBM cell line (Figure 7), sug-
gesting that the peptide may be useful for labeling glioblastomas in
general. The SBK4 peptide labeled both Gli36Δ5 and LN-229 flank
tumors to a similar extent as SBK2, but SBK4 labeling intensity de-
creased at a faster rate over time (Figures 6B and 7B). The levels of
Gli36Δ5 and LN-229 tumor labeling with SBK2 or SBK4 peptides
were significantly different from the scrambled control peptide, as ana-
lyzed with an unpaired Student’s t test. Two other peptides, SBK1 and
SBK3, bound the GBM tumors poorly in vivo, with no significant dif-
ference from the scrambled control peptide (Figures 6B and 7B).
Peptide Crossing of the Compromised Blood-Brain Barrier and
Recognition of Glioblastoma Tumors
Whereas the results of flank tumor labeling demonstrate that the
PTPμ peptides are capable of labeling GBM tumors in vivo, it was
important to determine whether these peptides can cross the blood-
brain barrier, which is compromised in glioblastomas, to reach phys-
iological targets in the brain. Athymic nude mice implanted with
LN-229-GFP or Gli36Δ5-GFP intracranial tumors were used for
PTPμ peptide labeling experiments. SBK2 or SBK4 peptide was in-
jected through the tail vein and allowed to circulate in the mouse for
25 minutes to permit binding to the glioma brain tumor and initial
clearance from nontumor tissue. The Maestro FLEX In Vivo Imaging
System cannot image through the skull. Therefore, the animals were
sacrificed, and the treated brain was removed and imaged whole or
sectioned into 1-mm coronal slices and analyzed using the Maestro
System as described above using filters appropriate for GFP, TR, or
Alexa-750 fluorescence (Figure 8). The location of the tumor in the
brain is indicated by GFP fluorescence. The TR scrambled control
peptide did not label the tumor (Figure 8A). The TR SBK4 peptide
crossed the compromised blood-brain barrier and bound to the main
glioma tumor mass (Figure 8B). This particular tumor protruded into
the skull, and a small piece of the skull is attached that contains GFP-
labeled tumor cells (Figure 8, B andC , on the left side of each image). The
tumor area was magnified four times for ease of visualization of the
coincident labeling of GFP and SBK4 within the Gli36Δ5 tumor
(Figure 8C , yellow-overlay image). India ink perfusion of the brain indi-
cates the location of the vasculature in that area of the brain (Figure 8D),
which is distinct from the labeling pattern observed with the SBK4
peptide. Quantitation of brain slice labeling in Gli36Δ5-GFP tumors
showed the SBK2 peptide labeled at a significantly higher level than
either scrambled peptide or PBS control injections (Figure 8E ). To-
gether, these studies suggest that the PTPμ peptide probes SBK2 and
Figure 6. PTPμ peptides SBK2 and SBK4 recognize Gli36Δ5 mouse flank tumors in vivo. TR- or Alexa-750 (AL)–conjugated PTPμ peptides
were administered intravenously to mice with xenograft flank tumors of Gli36Δ5 cells. (A) Fluorescent images of SBK2-AL peptide labeling.
Panel-labeled “before tx” (before time course) shows the animal autofluorescent background. The tumor cells are expressing GFP. (B) Time
course of peptide binding to flank tumors (n = 3 animals tested per peptide). Average normalized signals acquired in the tumor region of
interest were plotted. Error bars, SEM from the three animals. (C) ROIs shown over the tumor and nontumor skin. (D) Bright field image of the
flank tumor labeled in (A).
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SBK4 specifically bind to the extracellular PTPμ fragment, label
human GBM tumors, and can cross the compromised blood-brain
barrier to identify the GBM tumor noninvasively in vivo.
Discussion
Two biologic characteristics contribute to the lethality of many human
brain tumors: 1) their uncontrolled proliferation in the restricted cranial
space and 2) the highly dispersive nature of tumors such as glioblasto-
mas [1]. The rapid and extensive dispersal of GBMs results in the for-
mation of secondary masses throughout the brain, some of which occur
in inoperable regions. This, combined with an increased tumor load,
leads to rapid mortality [6]. MRI is limited in its ability to detect these
small clusters of glioblastoma cells that can form secondary masses [7].
Thus, MRI-guided surgical resections are likely to overlook GBM cells
that have dispersed away from the main tumor mass, leading to poor
prognosis. Clearly, the development of specific molecular diagnostics
is critical for the detection and eradication of GBM. In this article,
we report the identification of an extracellular fragment of PTPμ that
can be molecularly imaged in vivo and used as a unique biomarker of
GBM cells. Importantly, the peptides described in this article offer novel
molecular diagnostic tools that are able to cross the compromised blood-
brain barrier to label GBM tumors.
GBM cell dispersal occurs along characteristic pathways of anato-
mic structures in the brain that are rich in cell adhesion molecules
and extracellular matrix molecules that serve as permissive substrates
for cell migration [29,30]. GBM cell dispersal requires the production
of proteolytic enzymes [31], which gives the cell the ability to move
through its environment [29]. GBM cells overexpress growth factor
receptor protein tyrosine kinases and their ligands, an important pre-
requisite for tumor growth and dispersal [32]. The activity of the recep-
tor tyrosine kinases is normally kept in check by the opposing activity of
RPTPs such as PTPμ, which are important regulators of adhesion-
dependent signals [8–10].
Human tissue samples of GBM and noncancerous “normal” brain
from epileptic foci were examined by immunoblot analyses. These stud-
ies revealed a dramatic increase of a 55-kDa N-terminal extracellular
fragment of PTPμ in dispersive GBMs when compared with normal
brain. Using peptides that specifically recognize this PTPμ extracellular
fragment, it was determined that the PTPμ fragment is common to
high-grade glioblastomas. The PTPμ extracellular fragment is present
in human tumor “edge” samples, and the peptides are able to demarcate
tumor cells in tissue sections, suggesting that the peptides could be
used diagnostically for molecular imaging of dispersive brain tumors
or the tumor margin in vivo. To assess whether this is the case, experi-
ments were performed using a rodent flank humanGBM tumor model.
The proof-of-principle experiments used fluorescently labeled pep-
tide probes to image the tumor cells in live rodents using the Maestro
FLEX In Vivo Imaging System. Systemic introduction of the peptide
probes resulted in rapid and specific labeling of the flank tumors within
minutes. Labeling occurred primarily within the tumor and at the
tumor margin, indicating that the extracellular PTPμ fragment remains
associated with the tumor. Most importantly, the PTPμ peptides
crossed the compromised blood-brain barrier to specifically label GBM
tumor cells in the brain. Together, these data demonstrate that the
PTPμ peptide probes could be used as molecular indicators of high-
grade glioblastoma.
Figure 7. PTPμ peptides SBK2 and SBK4 recognize LN-229 mouse flank tumors in vivo. TR- or Alexa-750 (AL)–conjugated PTPμ peptides
were administered intravenously to mice with xenograft flank tumors of LN-229 cells. (A) Fluorescent images of SBK2-AL peptide labeling.
Panel-labeled “before tx” (before time course) shows the animal autofluorescent background. The tumor cells are expressing GFP. (B) Time
course of peptide binding to flank tumors (n = 3 animals tested per peptide). Average normalized signals acquired in the tumor region of
interest were plotted. Error bars, SEM from the three animals. (C) ROIs shown over the tumor and nontumor skin. (D) Bright field image of the
flank tumor labeled in A.
Neoplasia Vol. 12, No. 4, 2010 Detection of GBM with PTPμ Probes Burden-Gulley et al. 313
The development of the PTPμ peptide probes was based on a large
body of structural and functional data. The sites required for PTPμ-
mediated homophilic adhesion have been well characterized by our
laboratory and others [11,13–20,33]. The crystal structure of PTPμ
provided valuable information regarding which regions of each func-
tional domain are likely to be exposed to the extracellular environment
and therefore available for homophilic binding and detection by a pep-
tide probe. Of the four peptides generated, we found two that are com-
pelling as specific markers of high-grade GBM (SBK2 and SBK4). A
point of interest is that these peptides recognize two different domains
of PTPμ (SBK2: the MAM domain; SBK4: the Ig domain) that are
folded in a close conformation [19], and are both required for efficient
cell-cell adhesion [34].
We previously determined that PTPμ is cleaved at three different
sites to generate both a mature protein and, ultimately, an intracellular
fragment that is found in both the cytoplasm and the nucleus [21]. In
that study, we determined that cleavage of the extracellular domain of
PTPμ through a metalloprotease (a matrix metalloproteinase or A Dis-
integrin And Metalloprotease [ADAM]) was necessary for further pro-
cessing [21]. Although we cannot identify the site of cleavage because
metalloproteases lack a specific amino acid recognition sequence, it may
be that such an enzyme is functioning to yield the extracellular frag-
ment of PTPμ. Another type IIb RPTP, PTPκ is also cleaved by an
ADAM to release an extracellular fragment [35]; thus, the cleavage we
observe heremay be a common phenomenon. It is likely that cleavage of
other cell surface receptors also occurs inGBMs andmany other tumors.
In support of this, metalloproteases [36] and metalloprotease cleavage of
adhesion molecules are linked to tumor progression [37]. A similar
molecular detection strategy could be used with any other homophilic
or heterophilic-binding cell surface protein whose ligand-binding site is
Figure 8. PTPμ peptides SBK2 and SBK4 label LN-229 and Gli36Δ5 intracranial tumors in vivo. TR-conjugated PTPμ peptides were admin-
istered intravenously tomice with xenograft intracranial tumors of LN-229 or Gli36Δ5 cells. (A–C) Bright field images of brains containing LN-
229-GFP tumors are shown on the left after tail vein injection of the peptides. GFP fluorescence of the brains is shown second, indicating the
location of the LN-229-GFP tumor. TR fluorescent images of the brains are shown third. The overlay image of the GFP and TR is shown on
the far right. (A) Scrambled control peptide did not label the tumors. (B) The SBK4 peptide crossed the compromised blood-brain barrier to
label LN-229 tumors. (C) The SBK4 peptide labeling is shown at four timesmagnification to enhance visualization of the overlay of green and
red fluorescence, which appears as yellow. (D) India ink perfusion of the brains indicates the location of blood vessels in that region of the
brain. (E) Fluorescence quantitation of peptide binding in brain slices containing Gli36Δ5-GFP tumor cells labeled with SBK2-AL peptide (n=
6), scrambled SBK2-TR peptide (n = 7), or PBS (n = 6). Quantitation of SBK2-AL labeling of control brain slices (n = 4) is also shown. Error
bars, SE. Statistical significance from control calculated with the Student’s t-test is shown (*P < .001).
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known. A large variety of cell surface proteins, including other phos-
phatases, are cleaved at the cell surface [35,38–40]. These proteins
represent additional targets for the development of novelmolecular diag-
nostics [41]. Furthermore, the PTPμ peptides could be used as a starting
point to develop higher affinity small molecules with similar ligand-
binding capabilities.
In the context of this study, a question remains: What is the biologic
significance of the cleavage of PTPμ and shedding of the extracellular
fragment? Recently, we examined whether the absence of PTPμ in-
fluences the migratory behavior of glioblastoma cells in the complex
environment of the brain [12]. We found that full-length PTPμ influ-
ences contact-dependent signaling by negatively regulating migration of
glial cells [12]. Therefore, the loss of PTPμ protein expression through
proteolysis and fragment generation may be advantageous to GBM
during tumor progression. It is unclear whether the association of
the PTPμ fragment with dispersing GBM cells has an additional
functional role to modulate cell-cell adhesion or interaction with en-
dothelial cells, which also express PTPμ [24–28]. Alternatively, the
extracellular fragment may activate intracellular signaling cascades
by binding to cell surface PTPμ on other cells in the tumor micro-
environment. Because the extracellular fragment contains all the do-
mains of PTPμ required for efficient homophilic binding and it
maintains adhesive activity, it is intriguing to speculate that the
PTPμ shedding generates a “highway” for tumor cell migration in
the microenvironment.
Neurosurgeons routinely use stereotactic techniques and intraopera-
tive MRI in surgical resections. This allows them to identify and sample
tissue from distinct regions of the tumor such as the tumor edge or cen-
ter. Frequently, they also sample regions of brain on the tumor margin
that are outside the tumor edge that appear to be grossly normal but are
infiltrated by dispersing tumor cells on histologic examination. Such
surgical techniques have been instrumental in characterizing various
molecules associated with the invasive phenotype [42,43].With the dis-
covery of molecular diagnostics for GBM cells, intraoperative imaging
techniques could guide neurosurgical resection and eliminate the “edu-
cated guess” of the location of the tumor margin by the neurosurgeon.
Previous studies have determined that more extensive surgical resection
improves patient survival [5,44,45]. Thus, PTPμ peptide probes that
function as diagnostic molecular imaging agents have the potential to
increase patient survival. Currently available intraoperative imaging
devices could be retrofitted to visualize these PTPμ peptide probes.
Alternatively, the PTPμ peptides could be labeled with other agents to
identify the best imaging modality for visualizing small numbers of
dispersing GBM tumor cells. Such an approach has clear translational
applications and may lead to improved outcomes for patients with this
devastating disease.
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Figure W1. Gli36Δ5 flank tumors label with PTPμ peptides. Flank tumors of Gli36Δ5 cells were excised, fixed, and sectioned. The
Gli36Δ5 cells express GFP. Binding of the Texas Red–conjugated SBK2 and SBK4 peptides is shown. The peptides label both the tumor
cells and the area adjacent to the tumor.
Figure W2. LN-229 flank tumors label with PTPμ peptides. Flank tumors of LN-229 cells were excised, fixed, and sectioned. The LN-229
cells express GFP. Binding of the Texas Red–conjugated SBK2 and SBK4 peptides is shown. The peptides label both the tumor cells and
the area adjacent to the tumor.
